Felipe Inserra
Overview
Explore the profile of Felipe Inserra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1020
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanz R, Garcia Menendez S, Inserra F, Ferder L, Manucha W
World J Exp Med
. 2024 Jul;
14(2):91519.
PMID: 38948421
Mitochondrial dysfunction is a key driver of cardiovascular disease (CVD) in metabolic syndrome and diabetes. This dysfunction promotes the production of reactive oxygen species (ROS), which cause oxidative stress and...
2.
de Cavanagh E, Inserra F, Ferder L
Physiol Rep
. 2024 Jun;
12(12):e16094.
PMID: 38924381
The renin-angiotensin system (RAS)-a classical blood pressure regulator-largely contributes to healthy organ development and function. Besides, RAS activation promotes age-related changes and age-associated diseases, which are attenuated/abolished by RAS-blockade in...
3.
Sanz R, Garcia Menendez S, Inserra F, Ferder L, Manucha W
Curr Pharm Des
. 2024 Mar;
30(13):969-974.
PMID: 38551044
In metabolic syndrome and diabetes, compromised mitochondrial function emerges as a critical driver of cardiovascular disease, fueling its development and persistence, culminating in cardiac remodeling and adverse events. In this...
4.
Sanz R, Inserra F, Garcia Menendez S, Mazzei L, Ferder L, Manucha W
Curr Hypertens Rep
. 2023 Apr;
25(6):91-106.
PMID: 37052810
Purpose Of Review: To address the mechanistic pathways focusing on mitochondria dysfunction, oxidative stress, sirtuins imbalance, and other contributors in patient with metabolic syndrome and cardiovascular disease. Sodium glucose co-transporter...
5.
Elbert A, Castellaro C, Litwak L, Inserra F, Wassermann A, Sinay I
Medicina (B Aires)
. 2022 Jul;
82(4):576-590.
PMID: 35904915
The prevalence of type 2 diabetes mellitus (DM2) is increasing, generating a great impact both at individual and public health level. Nearly half of the patients with DM2 develop impaired...
6.
Mariani J, Antonietti L, Tajer C, Ferder L, Inserra F, Sanchez Cunto M, et al.
PLoS One
. 2022 May;
17(5):e0267918.
PMID: 35622854
Background: The role of oral vitamin D3 supplementation for hospitalized patients with COVID-19 remains to be determined. The study was aimed to evaluate whether vitamin D3 supplementation could prevent respiratory...
7.
Campbell N, Whelton P, Orias M, Wainford R, Cappuccio F, Ide N, et al.
J Hum Hypertens
. 2022 May;
37(6):428-437.
PMID: 35581323
No abstract available.
8.
Inserra F, Forcada P, Castellaro A, Castellaro C
Front Med (Lausanne)
. 2021 Dec;
8:765924.
PMID: 34888327
The kidney-heart relationship has raised interest for the medical population since its vast and complex interaction significantly impacts health. Chronic kidney disease (CKD) generates vascular structure and function changes, with...
9.
Inserra F, Tajer C, Antonietti L, Mariani J, Ferder L, Manucha W
Vaccine
. 2021 Jul;
39(35):4930-4931.
PMID: 34303561
No abstract available.
10.
Mariani J, Tajer C, Antonietti L, Inserra F, Ferder L, Manucha W
Trials
. 2021 Feb;
22(1):111.
PMID: 33522946
Objectives: To evaluate whether a single high dose of oral cholecalciferol improves the respiratory outcomes as compared with placebo among adults COVID-19 patients at moderate risk of clinical complications. Trial...